You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020313023
Dec 20205007
Jan 202113209
Feb 20215407
Mar 202162010
Apr 20215209
May 20211504
Jun 20210011
Jul 2021003
Aug 2021004
Sep 2021009
Oct 202132023
Nov 202165024
Dec 20212602
Jan 20223202
Feb 20222805
Mar 20223405
Apr 20225808
May 20227406
Jun 20225604
Jul 20223206
Aug 20225405
Sep 20225004
Oct 20224802
Nov 20226806
Dec 20221802
Jan 20233204
Feb 20238005
Mar 20233601
Apr 20234404
May 20232205
Jun 20232202
Jul 20234607
Aug 20233002
Sep 20233003
Oct 20235005
Nov 20235606
Dec 20234003
Jan 20241800
Feb 20243402
Mar 20243200
Apr 20241201
May 20243201
Jun 20243903
Jul 202411003
Aug 20241803
Sep 20242201
Oct 20241803
Nov 20241000
Dec 20242802
Jan 20253608
Feb 20251406
Mar 2025001
Apr 2025103
May 2025007
Jun 2025002
Total22650293